Menu
Search icon
  1. Home Page
    2. ›
  2. Counties
    3. ›
  3. Westchester
    4. ›
  4. 10805
    5. ›
  5. NEW YORK R&D CENTER FOR TRANSLATIONAL MEDICINE AND THERAPEUTICS, INC.

NEW YORK R&D CENTER FOR TRANSLATIONAL MEDICINE AND THERAPEUTICS, INC.

Company claim

Is this your business?

Get access!

Company Details

Name: NEW YORK R&D CENTER FOR TRANSLATIONAL MEDICINE AND THERAPEUTICS, INC.
Jurisdiction: New York
Legal type: DOMESTIC BUSINESS CORPORATION
Status: Active
Date of registration: 07 Jun 2013 (12 years ago)
Entity Number: 4414773
ZIP code: 10805
County: Westchester
Place of Formation: New York
Address: 173 KENSINGTON OVAL, NEW ROCHELLE, NY, United States, 10805

Shares Details

Shares issued 200

Share Par Value 0

Type NO PAR VALUE

Chief Executive Officer

Name Role Address
HUI BIN SUN Chief Executive Officer 173 KENSINGTON OVAL, NEW ROCHELLE, NY, United States, 10805

DOS Process Agent

Name Role Address
NEW YORK R&D CENTER FOR TRANSLATIONAL MEDICINE AND THERAPEUTICS, INC. DOS Process Agent 173 KENSINGTON OVAL, NEW ROCHELLE, NY, United States, 10805

Unique Entity ID

A UEI is a government-provided number, like a tax ID number, that’s used to identify businesses eligible for federal grants, awards and contracts.

Note: In April 2022, the federal government replaced its old identifier of choice, the Data Universal Numbering System (DUNS) number, with a government-issued UEI. Now all the federal government’s Integrated Award Environment systems use UEI numbers instead of DUNS numbers. So any entity doing business with the federal government must register for a UEI.

Unique Entity ID:
JBDNWL5M9D43
CAGE Code:
6XU64
UEI Expiration Date:
2025-08-08

Business Information

Doing Business As:
NEW YORK R & D CENTER FOR TRANSLATIONAL MEDICINE & THERAPEUTICS INC
Activation Date:
2024-08-12
Initial Registration Date:
2013-06-19

Commercial and government entity program

The The Commercial And Government Entity Code (CAGE) is assigned by the Department of Defense's Defense Logistics Agency (DLA) and represents your company's physical address for GSA's mailings, payments, and administrative records.

Note: A CAGE Code enables a company to contract with the U.S. government, allowing bid on government contracts and to receive government payments. Also for business this means that it's a Verified business entity and Has a validated physical address.

CAGE number:
6XU64
Status:
Active
Type:
Non-Manufacturer
CAGE Update Date:
2024-08-12
CAGE Expiration:
2029-08-12
SAM Expiration:
2025-08-08

Contact Information

POC:
DAVID T. FUNG

History

Start date End date Type Value
2015-06-18 2019-06-20 Address 81 BISCHOFF AVE, CHAPPAQUA, NY, 10514, USA (Type of address: Chief Executive Officer)
2015-06-18 2019-06-20 Address 81 BISCHOFF AVE, CHAPPAQUA, NY, 10514, USA (Type of address: Principal Executive Office)
2013-06-07 2019-06-20 Address 81 BISCHOFF AVE, CHAPPAQUA, NY, 10514, USA (Type of address: Service of Process)

Filings

Filing Number Date Filed Type Effective Date
220217002905 2022-02-17 BIENNIAL STATEMENT 2022-02-17
190620060358 2019-06-20 BIENNIAL STATEMENT 2019-06-01
170605007789 2017-06-05 BIENNIAL STATEMENT 2017-06-01
150618006216 2015-06-18 BIENNIAL STATEMENT 2015-06-01
130607000695 2013-06-07 CERTIFICATE OF INCORPORATION 2013-06-07

USAspending Awards / Financial Assistance

Date:
2025-04-10
Link:
View on USAspending
Awarding Agency Name:
Department of Defense
Transaction Description:
A NOVEL TREATMENT TO MITIGATE COMPLICATIONS OF ACL RECONSTRUCTION
Obligated Amount:
0.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2024-06-20
Link:
View on USAspending
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
EXOSOME DRUG FOR TENDINOPATHY - PROJECT SUMMARY TENDINOPATHY IS AN AGE-RELATED TENDON DISORDER CHARACTERIZED BY TENDON DETERIORATION AND IS ASSOCIATED WITH PAIN, SWELLING AND IMPAIRED PERFORMANCE, AND OFTEN LEADS TO TENDON RUPTURE. GIVEN THAT THERE IS NO DISEASE- MODIFYING THERAPEUTIC ON THE MARKET, OUR CENTRAL GOAL IS TO DEVELOP AND COMMERCIALIZE A NOVEL BIOLOGIC AS AN EFFECTIVE AND SAFE TREATMENT FOR TENDINOPATHY. THE PRODUCT TO BE DEVELOPED IS ALTENEX, A DISEASE-MODIFYING BIOLOGIC DRUG CONSISTING OF EXOSOMES GENERATED BY ALLOGENEIC HUMAN BONE MARROW-DERIVED MESENCHYMAL STEM CELLS (BM-MSCS) GROWN ON A NOVEL SPECIALIZED 3D SCAFFOLD FOR THE TREATMENT OF TENDINOPATHY. ALTENEX IS AN EXCITING OUTCOME FOR OUR EFFORT IN DEVELOPING A STEM CELL-BASED BIOLOGIC PRODUCT BASED ON A SCALABLE PRODUCTION PROCESS. HUMAN BM-MSCS FROM A READILY AVAILABLE STEM CELL BANK ARE CULTURED ON UNIQUELY ENGINEERED “NANOPRIME” SCAFFOLDS FABRICATED WITH ELECTROSPUN ALIGNED POLYCAPROLACTONE (PCL) FIBERS. THESE MASS-PRODUCED SCAFFOLDS EMULATE THE 3D MICROENVIRONMENT THAT CARRIES THE PHYSICAL CUES TO “GUIDE” THE MSCS TOWARD TENOCYTIC DIFFERENTIATION AND, IN DOING SO, SECRETE EXOSOMES WITH THERAPEUTIC POTENTIAL IN TENDINOPATHY. IN OUR PRELIMINARY STUDIES, ALTENEX PRODUCED FROM XENO-FREE DEVELOPMENT-GRADE HUMAN BM-MSCS WAS CHARACTERIZED AS TYPICAL EXOSOMES. THE EXOSOME IDENTITY OF ALTENEX WAS CONFIRMED BY ITS EXOSOMAL PROTEIN MARKERS. EXCITINGLY, WE FOUND INTRA-TENDINOUS INJECTION OF ALTENEX, INTO RAT ACHILLES TENDONS WITH TENDINOPATHY MITIGATED HISTOLOGIC FEATURES OF TENDINOPATHY. THESE ENCOURAGING DATA SUPPORT THE FEASIBILITY OF DEVELOPING ALTENEX AS A BIOLOGIC DRUG FOR TENDINOPATHY CONSISTING OF ALLOGENEIC EXOSOMES AND LED US TO HYPOTHESIZE THAT ALTENEX EXERTS A THERAPEUTIC EFFECT ON MITIGATING TENDINOPATHY WITH MINIMAL, IF ANY, ADVERSE EFFECTS. TO TEST THE HYPOTHESIS, TWO SPECIFIC AIMS ARE PROPOSED. IN AIM 1, WE WILL DETERMINE THE EFFICACIES, SAFETY AND PHARMACOKINETICS OF ALTENEX USING A COLLAGENASE-INDUCED RAT MODEL OF TENDINOPATHY. SPECIFICALLY, WE WILL FIRST IDENTIFY THE OPTIMAL DOSE AND DOSE SCHEDULE FOR ALTENEX BASED ON HISTOLOGIC SCORING. THEN, USING THE OPTIMAL DOSE AND DOSE SCHEDULE, WE WILL DETERMINE THE THERAPEUTIC EFFECT OF ALTENEX ON MITIGATING TENDINOPATHY PATHOLOGY, IMPROVING TENDON MECHANICAL PROPERTIES, AND RELIEVING PAIN BEHAVIORS. FURTHERMORE, WE WILL EVALUATE THE SAFETY AND PHARMACOKINETICS OF ALTENEX. IN AIM 2, WE WILL DETERMINE THE EFFICACY AND SAFETY OF ALTENEX ON TENDINOPATHY IN RABBITS. RABBITS WITH A SEVERE STAGE OF COLLAGENASE-INDUCED ACHILLES TENDINOPATHY WILL BE TREATED WITH ALTENEX AND COMPARED AGAINST CONTROLS. THE EFFICACY MEASUREMENTS WILL FOCUS ON THE PATHOLOGY AND MECHANICAL PROPERTIES OF THE DISEASED TENDON, THE PARAMETERS THAT HAVE BEEN WELL-ESTABLISHED IN THIS RABBIT MODEL. FURTHERMORE, THE SAFETY OF ALTENEX TREATMENT WILL BE EVALUATED BY CLINICAL OBSERVATIONS AND CLINICAL PATHOLOGY, WITH PARTICULAR ATTENTION TO LOCAL TOXICITIES DUE TO INTERACTIONS ALTENEX WITH THE TISSUE AT THE SITE OF ADMINISTRATION. THIS PRECLINICAL STUDY IS A CRITICAL STEP THAT ADVANCES THE TRANSLATION OF ALTENEX TOWARD THE CLINICAL PHASE AND ULTIMATELY AN FDA-APPROVED DRUG FOR TENDINOPATHY.
Obligated Amount:
766269.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2022-09-23
Link:
View on USAspending
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
MIRNA DRUG FOR TENDINOPATHY - PROJECT SUMMARY TENDINOPATHY IS A TENDON DISORDER THAT IS HIGHLY PREVALENT IN THE AGED POPULATION. IT IS CHARACTERIZED BY TENDON DETERIORATION THAT OFTEN LEADS TO TENDON RUPTURE, AND IS ASSOCIATED WITH PAIN, SWELLING AND IMPAIRED PERFORMANCE. THERE IS CURRENTLY NO CURE FOR TENDINOPATHY AND AN URGENT NEED FOR EFFECTIVE TREATMENTS FOR TENDINOPATHY. THE TECHNOLOGY TO BE DEVELOPED IS MICRORNA (MIR)-221-5P FOR THE TREATMENT OF TENDINOPATHY. OUR PRELIMINARY STUDIES IDENTIFIED THAT MIR-221-5P EXHIBITED A THERAPEUTIC EFFECT IN A RODENT MODEL OF TENDINOPATHY AND MAY EXERT ITS THERAPEUTIC EFFECT, AT LEAST IN PART, BY SUPPRESSING EXPRESSION OF PRO-INFLAMMATORY MEDIATORS THAT CONTRIBUTE TO THE PATHOGENESIS OF TENDINOPATHY. THIS PROJECT WILL TEST THE HYPOTHESIS THAT CHEMICALLY MODIFIED MIR-221-5P EXERTS AN ENHANCED EFFECT ON MITIGATING TENDINOPATHY. THE PHASE II STUDY WILL FOCUS ON PROVIDING CRITICAL EVIDENCE TOWARDS DEVELOPING MIR-221-5P AS AN FDA-APPROVED PRODUCT FOR THE TREATMENT OF TENDINOPATHY. IN AIM 1, WE WILL DETERMINE THE CHEMICAL FORMULATION AND TREATMENT CONDITION OF MIR-221-5P USING A COLLAGENASE- INDUCED MODEL OF TENDINOPATHY. IN AIM 2, WE WILL DETERMINE THE EFFICACY AND SAFETY OF MIR-221-5P ON TENDINOPATHY IN RABBITS. SUCCESSFUL COMPLETION OF THE PROPOSED STUDIES WILL IDENTIFY MIR-221-5P AS A NEW DRUG FOR THE TREATMENT OF TENDINOPATHY AND OTHER CHRONIC INFLAMMATORY DISEASES.
Obligated Amount:
1866402.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2024-05-21
Link:
View on USAspending
Awarding Agency Name:
Department of Defense
Transaction Description:
A NOVEL MICRORNA-BASED STRATEGY FOR THE REPAIR OF INJURED TENDONS EXTEND THE PERIOD OF PERFORMANCE 1. PER SECTION 711 OF THE NATIONAL DEFENSE AUTHORIZATION ACT (NDAA) 2019, THE US ARMY MEDICAL RESEARCH ACQUISITION ACTIVITY (USAMRAA), US ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND (USAMRDC) TRANSFERRED TO THE DEFENSE HEALTH AGENCY (DHA) FROM THE U.S. ARMY EFFECTIVE 01 OCTOBER 2022. THIS MODIFICATION REFLECTS CHANGES CONSISTENT WITH THE TRANSFER TO DHA
Obligated Amount:
0.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2022-05-09
Link:
View on USAspending
Awarding Agency Name:
Department of Defense
Transaction Description:
A NOVEL MICRORNA-BASED STRATEGY FOR THE REPAIR OF INJURED TENDONS
Obligated Amount:
725000.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00

Reviews Leave a review

This company hasn't received any reviews.

Related by officers

No related officers

Related by address

173 KENSINGTON OVAL, NEW ROCHELLE, NY, United States, 10805

NATHERAS INC.

Date of last update: 26 Mar 2025

Sources: New York Secretary of State

Privacy policy Policy
About us About us
Contacts Contact us

© 2025 bizyork.com, Part of Big Data Integrated